Importantly, inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) and/or activation of farnesoid X receptor (FXR) using clinically relevant drugs, GKT137831 and obeticholic acid (OCA), respectively, alleviated hepatic dysfunctions in MPTCs at nontoxic concentrations, thereby suggesting MPTC utility for screening the efficacy and toxicity of anti-NASH/fibrosis drugs. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.